IMO, along with the company being a less attractive b/o candidate with so many (Pona) partners, the cash if Pona is sold off can be used to cleanup some complicated loans from the balance sheet.
Then, Ariad is a much simpler, higher valuation as a primarily lung cancer biotech with a very promising drug coming on market, going 1st line, with a solid pipeline behind it.
Market Data 
Markets 
AI
